文献速递腹部介入MR

LI-RADS 非放射治疗应答评估 2024 版:经动脉化疗栓塞治疗肝细胞癌的诊断效能

LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.
PubMed 文献 · Eur Radiol · 2025-10-10

本研究回顾性纳入 167 例经 TACE 后手术的 HCC 患者,以病理坏死为参考标准,评估 LI-RADS v2024 非放射 TRA 的诊断效能。LR-TR Viable 预测不完全坏死的敏感度 70.1%、特异度 97.7%;加入辅助特征后敏感度提高至 77.6% 且特异度未显著下降。

要点

  • LR-TR Viable 预测不完全坏死敏感度 70.1%、特异度 97.7%。
  • LR-TR Nonviable 预测完全坏死敏感度 77.3%、特异度 81.0%。
  • 加入辅助特征后敏感度 77.6% vs 70.1%,特异度 88.6% vs 97.7%。

核心结论

  • LI-RADS v2024 非放射 TRA 在评估 TACE 后 HCC 应答方面表现出良好的诊断效能,辅助特征的使用提高了检测残留存活肿瘤的敏感度,支持其在不确定病例中的临床效用。

研究设计与样本

  • 回顾性单中心研究,纳入 167 例接受 TACE 后手术的 HCC 患者(平均年龄 59 岁 ± 10,136 名男性),由两名放射科医师独立评估治疗后增强 MRI,采用 LI-RADS 2024 非放射 TRA 算法,以组织病理学结果(完全坏死 44/191 vs 不完全坏死 147/191)为参考标准。

诊断标准与关键数值

  • LR-TR Viable 预测不完全坏死:敏感度 70.1%(95%CI 0.63-0.77),特异度 97.7%(95%CI 0.93-0.98)。
  • LR-TR Nonviable 预测完全坏死:敏感度 77.3%(95%CI 0.65-0.90),特异度 81.0%(95%CI 0.75-0.87)。
  • 加入辅助特征后检测不完全坏死:敏感度 77.6% vs 70.1%(p=0.003),特异度 88.6% vs 97.7%(p=0.134)。

临床应用与阅片要点

  • 作者认为辅助特征的使用可优化 TACE 后评估和 HCC 管理的临床决策。
  • 辅助特征在不确定病例中具有临床效用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVES: The 2024 version of the Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Assessment (TRA) introduces two distinct algorithms: nonradiation TRA and radiation TRA. We aimed to assess the diagnostic performance of LI-RADS v2024 nonradiation TRA in evaluating hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).

METHODS: This retrospective single-center study enrolled 167 patients (mean age, 59 years ± 10 (standard deviation), 136 men) with HCC who underwent TACE followed by surgery. Post-treatment contrast-enhanced MRI was independently evaluated by two radiologists using the LI-RADS 2024 nonradiation TRA algorithm. Histopathologic results (complete necrosis (44/191) vs. incomplete necrosis [147/191]) served as the reference standard. Sensitivity, specificity, and accuracy of LI-RADS Treatment Response (LR-TR) categories were calculated. The impact of ancillary features (AFs) on diagnostic performance was analyzed using the McNemar test.

RESULTS: For predicting incomplete necrosis, the LR-TR Viable category showed a sensitivity of 70.1% (95% CI: 0.63-0.77) and specificity of 97.7% (95% CI: 0.93-0.98). For predicting complete necrosis, the LR-TR Nonviable category demonstrated a sensitivity of 77.3% (95% CI: 0.65-0.90) and specificity of 81.0% (95% CI: 0.75-0.87). Incorporating AFs significantly improved sensitivity for detecting incomplete necrosis (77.6% vs. 70.1%, p = 0.003) without compromising specificity (88.6% vs. 97.7%, p = 0.134).

CONCLUSION: LI-RADS v2024 nonradiation TRA demonstrated good diagnostic performance in assessing HCC response after TACE. The use of AFs enhanced sensitivity for detecting residual viable tumors, supporting their clinical utility in equivocal cases.

KEY POINTS: Question The diagnostic performance of the 2024 updated Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response Assessment (TRA), particularly the role of ancillary features (AFs), requires evaluation. Findings LI-RADS v2024 nonradiation TRA performed well in predicting histopathologic necrosis, with AFs significantly improving sensitivity for viability prediction. Clinical relevance The application of AFs is recommended to optimize post-TACE assessment and clinical decision-making for HCC management.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang D, Lyu R, Zhang Y, et al. LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization. Eur Radiol. 2025. PMID: 41071276. doi:10.1007/s00330-025-12047-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。